Pretargeted molecular imaging and radioimmunotherapy.
Pretargeted molecular imaging and radioimmunotherapy.
复制标题
DOI：
10.7150/thno.3582
复制
发表时间：
2012
期刊：
影响因子：
12.4
通讯作者：
Sharkey RM
中科院分区：
文献类型：
--
作者：
Goldenberg DM;Chang CH;Rossi EA;J W;McBride;Sharkey RM
预靶向是一个多步骤过程，首先将未标记的双特异性抗体 (bsMAb) 凭借其抗肿瘤结合位点定位在肿瘤内，然后施用小的、快速清除的放射性标记化合物，然后将其附着到 bsMAb 的其他部分。该化合物的快速清除能力显着减少了肿瘤外部的辐射暴露，其小尺寸允许快速递送至肿瘤，在不到 1 小时内产生优异的肿瘤/非肿瘤比率。与抗半抗原抗体结合的半抗原、与链霉亲和素结合的生物素或与互补寡核苷酸序列结合的寡核苷酸都已被放射性标记以供预靶向使用。本综述将重点关注高度灵活的抗半抗原 bsMAb 平台，该平台已用于靶向多种放射性核素进行成像（SPECT 和 PET）以及治疗肿瘤。
Pretargeting is a multi-step process that first has an unlabeled bispecific antibody (bsMAb) localize within a tumor by virtue of its anti-tumor binding site(s) before administering a small, fast-clearing radiolabeled compound that then attaches to the other portion of the bsMAb. The compound's rapid clearance significantly reduces radiation exposure outside of the tumor and its small size permits speedy delivery to the tumor, creating excellent tumor/nontumor ratios in less than 1 hour. Haptens that bind to an anti-hapten antibody, biotin that binds to streptavidin, or an oligonucleotide binding to a complementary oligonucleotide sequence have all been radiolabeled for use by pretargeting. This review will focus on a highly flexible anti-hapten bsMAb platform that has been used to target a variety of radionuclides to image (SPECT and PET) as well as treat tumors.
登录
查看更多内容
影响因子：
9.3
作者：
Goldenberg, David M.;Rossi, Edmund A.;Chang, Chien-Hsing
通讯作者：
Chang, Chien-Hsing
影响因子：
4.3
作者：
GEISSLER, F;ANDERSON, SK;PRESS, O
通讯作者：
PRESS, O
影响因子：
3.8
作者：
Ferl, GZ;Wu, AM;DiStefano, JJ
通讯作者：
DiStefano, JJ
影响因子：
11.5
作者：
Chang, Chien-Hsing;Rossi, Edmund A.;Goldenberg, David M.
通讯作者：
Goldenberg, David M.
影响因子：
1.5
作者：
ABDELNABI, H;DOERR, RJ;SCHWEIGHARDT, S
通讯作者：
SCHWEIGHARDT, S